1、 伍珊珊. 房颤患者服用华法林抗凝质量及其与SAMe-TT2 R2评分的关系[D]. 南方医科大学, 2019. 伍珊珊. 房颤患者服用华法林抗凝质量及其与SAMe-TT2 R2评分的关系[D]. 南方医科大学, 2019.
2、 ROLDAN V, CANCIO S, GALVEZ J, et al. The SAMe-TT2R2 score predicts poor anticoagulation control in af patients: a prospective “real-world” inception cohort study[J]. Am J Med, 2015, 128(11): 1237-1243. ROLDAN V, CANCIO S, GALVEZ J, et al. The SAMe-TT2R2 score predicts poor anticoagulation control in af patients: a prospective “real-world” inception cohort study[J]. Am J Med, 2015, 128(11): 1237-1243.
3、 陈文文, 党和勤, 耿涛,等. SAMe-TT2R2评分对非瓣膜性华法林抗凝控制质量的预测能力评价[J]. 中国医院药学杂志, 2017, 37(20): 2072-2076. 陈文文, 党和勤, 耿涛,等. SAMe-TT2R2评分对非瓣膜性华法林抗凝控制质量的预测能力评价[J]. 中国医院药学杂志, 2017, 37(20): 2072-2076.
4、 APOSTOLAKIS S, SULLIVAN R M, OLSHANSKY B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score[J]. Chest, 2013, 144(5): 1555-1563. APOSTOLAKIS S, SULLIVAN R M, OLSHANSKY B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score[J]. Chest, 2013, 144(5): 1555-1563.
5、 VEEGER N J, PIERSMA-WICHERS M, TIJSSEN J G, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. a retrospective study of 2 300 consecutive patients with venous thromboembolism[J]. Br J Haematol, 2005, 128(4): 513-519. VEEGER N J, PIERSMA-WICHERS M, TIJSSEN J G, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. a retrospective study of 2 300 consecutive patients with venous thromboembolism[J]. Br J Haematol, 2005, 128(4): 513-519.
6、 CONNOLLY S J, POGUE J, EIKELBOOM J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range[J]. Circulation, 2008, 118(20): 2029-2037. CONNOLLY S J, POGUE J, EIKELBOOM J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range[J]. Circulation, 2008, 118(20): 2029-2037.
7、 JONES M, MCEWAN P, MORGAN C L, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population[J]. Heart, 2005, 91(4): 472-477. JONES M, MCEWAN P, MORGAN C L, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population[J]. Heart, 2005, 91(4): 472-477.
8、 中华医学会心血管病学分会, 中国老年学学会心脑血管病专业委员会. 华法林抗凝治疗的中国专家共识[J]. 中华内科杂志, 2013, 52(1): 76-82. 中华医学会心血管病学分会, 中国老年学学会心脑血管病专业委员会. 华法林抗凝治疗的中国专家共识[J]. 中华内科杂志, 2013, 52(1): 76-82.